Introduction

Epigenetic control is essential for development and differentiation, and this control mechanism is very frequently deregulated in cancer. Several small molecule inhibitors have been developed in recent years that have either been approved for clinical use or are in preclinical and clinical trials. This conference will focus on basic and clinical aspects of targeting a broad panel of epigenetic proteins in cancer, either as monotherapies, or as combination therapies, including the use of immune checkpoint inhibitors to increase drug sensitivity and overcome chemoresistance.

Register now

Target audience

Scientists in academia and industry who are interested in how Epigenetic targeted therapy can be used for genetically targeted and combination therapies, including immune-based cancer therapies. The conference will focus on the mechanistic aspects of gene regulation and cellular plasticity, drug development as well as clinical trials using epigenetic targeted therapies.  

Topics to be covered:

• Epigenetic Regulation in Cancer Development and Maintenance
• Novel Epigenetic Targets 
• Drug Resistance
• Combination Therapies
• Clinical Trials

Scientific Programme Committee:

• Kristian Helin, UK (Chair)
• Cigall Kadoch, USA
• Mark Dawson, Australia
• Ho Man Chan, USA
• Jingwen Zhang, USA

Follow us on X for updates @EACRnews and engage with the conference with #eacrCancerEpigenetics

Contact

If you have any queries that are not answered on this webpage, please contact us using the details below.

Hannah Barrs
Conference Officer
Hannah.barrs@eacr.org